In the published article titled “Efficacy of immune checkpoint inhibitor with or without chemotherapy for nonsquamous NSCLC with malignant pleural effusion: a retrospective multicenter cohort study,” JTO Clin Res Rep. 2022;3:100355:
The author of this paper have discovered several errors in the published version in Fig 3 and Table 1 of the supplementary data. We have included the correct figure and table here. In Table 1, in the ''Treatment regimen'' section of all patients, the proportion of Pembrolizumab was wrong. The "32 (74)" was incorrect; it should have been "32 (50)". The authors deeply apologize for any inconvenience caused, and would like to correct these corrigendums in order to not mislead readers.
Figure 3.
Progression free survival in ICI/chemo cohort adjusted by PSM (N=42)
Table 1.
Patient Characteristics in PD-L1 High Cohort and Comparison Between Pembrolizumab Group and Chemotherapy Plus ICI Group Adjusted by Propensity Score Matching (N = 64)
| Patient Characteristics | All Patients (N = 64) | Pembrolizumab Group (N = 32) | ICI Plus Chemotherapy Group (N = 32) | p Value |
|---|---|---|---|---|
| Age (y) | ||||
| Median (range) | 69.5 (46-81) | 69.5 (48-81) | 69.5 (46-79) | 0.6331 |
| <75 y | 52 (81) | 26 (81) | 26 (81) | 1.0000 |
| ≥75 y | 12 (19) | 6 (19) | 6 (19) | |
| Sex | ||||
| Male | 44 (69) | 22 (69) | 22 (69) | 1.0000 |
| Female | 20 (31) | 10 (31) | 10 (31) | |
| Smoking status | ||||
| Never-smoker | 14 (22) | 7 (22) | 7 (22) | 1.0000 |
| Current or former smoker | 50 (78) | 25 (78) | 25 (78) | |
| ECOG PS | ||||
| 0-1 | 46 (72) | 22 (68) | 24 (75) | 0.5782 |
| 2-4 | 18 (28) | 10 (31) | 8 (25) | |
| Histology | ||||
| Adenocarcinoma | 57 (89) | 28 (88) | 29 (91) | 0.6888 |
| Other | 7 (11) | 4 (13) | 3 (9) | |
| PD-L1 status | ||||
| 50-74% | 23 (36) | 11 (34) | 12 (38) | 0.7945 |
| 75-100% | 41 (64) | 21 (66) | 20 (62) | |
| Pleural fluid cytology | ||||
| Confirmed | 31 (48) | 15 (47) | 16 (50) | 0.8025 |
| Volume of malignant pleural effusion | ||||
| Small | 16 (25) | 7 (22) | 9 (28) | 0.5637 |
| Large | 48 (75) | 25 (78) | 23 (72) | |
| Pleural intervention | ||||
| Not performed | 27 (42) | 13 (41) | 14 (44) | 0.8459 |
| Thoracentesis | 21 (33) | 10 (31) | 11 (34) | |
| Chest tube drainage | 16 (25) | 9 (28) | 7 (22) | |
| Pleurodesis | ||||
| Performed | 11 (17) | 6 (19) | 5 (16) | 0.7404 |
| Metastatic site | ||||
| Liver metastasis | 4 (6) | 1 (3) | 3 (9) | 0.3017 |
| Brain metastasis | 8 (13) | 3 (9) | 5 (16) | 0.4497 |
| Bone metastasis | 22 (34) | 12 (38) | 10 (31) | 0.5986 |
| Adrenal metastasis | 7 (11) | 3 (9) | 4 (13) | 0.6888 |
| Treatment regimen | ||||
| Pembrolizumab | 32 (50) | 32 (100) | ||
| CBDCA/PEM/Pembrolizumab | 20 (31) | 20 (63) | ||
| CDDP/PEM/Pembrolizumab | 3 (5) | 3 (9) | ||
| CBDCA/PEM/Atezolizumab | 2 (4) | 2 (6) | ||
| CBDCA/PTX/BEV/Atezolizumab | 5 (8) | 5 (16) | ||
| CBDCA/nab-PTX/Atezolizumab | 2 (3) | 2 (6) |
BEV, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor; nab-PTX, nanoparticle albumin-bound paclitaxel; PD-L1, programmed death ligand 1; PEM, pemetrexed; PTX, paclitaxel.
Address for correspondence: Hayato Kawachi, MD. E-mail: kwhat0729@gmail.com